Arcturus Therapeutics Holdings Inc. Research And Development Expense

• Arcturus Therapeutics Holdings Inc. showed a decrease of -42.5% in Research And Development Expense from 2024 to 2025.
• This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Research And Development Expense has grown by 560.8%.
• Historical annual values: Fiscal year 2025: $112.21 million | Fiscal year 2024: $195.16 million | Fiscal year 2023: $192.13 million | Fiscal year 2022: $147.75 million | Fiscal year 2021: $173.76 million | Fiscal year 2020: $57.85 million | Fiscal year 2019: $33.64 million | Fiscal year 2018: $16.98 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026